Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivaglobin (SCIG) in Multifocal Motor Neuropathy
NCT00701662Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Nov 2007
- Primary completion
- Jan 2009
- Modality
- Biologic
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of IgPro10 in multifocal motor neuropathy (MMN), sponsored by CSL Limited. Primary endpoints: Change From Baseline to Week 24 in Muscle Strength and Mean Overall MRC Score at 24 weeks. Started Nov 2007; status: completed.
02
Drugs
IgPro10
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT00701662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701662.